<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926562</url>
  </required_header>
  <id_info>
    <org_study_id>14147</org_study_id>
    <nct_id>NCT00926562</nct_id>
  </id_info>
  <brief_title>A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients</brief_title>
  <acronym>DIRECT</acronym>
  <official_title>A Randomized, Double-blinded Comparison of Iopromide and Iodixanol in Renally Impaired Patients Undergoing Cardiac Catheterization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to find out which contrast agent has less kidney toxicity in renal
      impaired patients undergoing cardiac angiography or percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the diagnosis and treatment of coronary heart disease, patients should undergo cardiac
      angiography or percutaneous coronary intervention (PCI). In those procedures, the
      investigators should use the contrast media, and it may cause kidney toxicity especially in
      the patients with chronic renal insufficiency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients exhibiting a relative increase in serum creatinine &gt;= 50% from baseline.</measure>
    <time_frame>day 3 postreatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients developing acute renal failure.</measure>
    <time_frame>day 30 postreatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of a postdose SCr increase ≧25%, a postdose SCr increase ≧1mg/dL, a postdose SCr increase ≧0.5mg/dL, a postdose eGFR decrease ≧25%</measure>
    <time_frame>days 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">592</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Iopromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ultravist 370 mgl/ml, injection of intra-artery during cardiac interventional operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iodixanol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Visipaque 320 mgl/ml, injection of intra-artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iopromide (Ultravist)</intervention_name>
    <description>Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM</description>
    <arm_group_label>Iopromide</arm_group_label>
    <other_name>Ultravist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodixanol (Visipaque)</intervention_name>
    <description>Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM</description>
    <arm_group_label>Iodixanol</arm_group_label>
    <other_name>Visipaque</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old or older

          -  Plan to undergo Cardiac Catheterization

          -  Signed ICF

          -  eGFR: 30~59 mL/min/1.73m2

        Exclusion Criteria:

          -  Pregnancy

          -  Under dialysis

          -  Conditions interfering with Cardiac Catheterization

          -  Participation in other trials

          -  Allergic to X-ray contrast media

          -  Administration of any investigational drug within the previous 30 days

          -  Intra-arterial or intravenous administration of iodinated contrast medium from 7 days
             before to 72 hours after the administration of study drug

          -  Left ventricular ejection fraction (LVEF) less than 30% by ultrasound examination

          -  Intake of any nephrotoxic medications 24 hours before or after the administration of
             study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yundai Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing CHAO-YANG Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Armed Police Forces</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Shi Jing Shan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Xiangya</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China-Japan Union Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jinlin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital affiliated to the second millitary medical university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teda International Cardiovascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300457</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital Affiliated to Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital affiliated to Zhejiang</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <last_update_submitted>June 24, 2011</last_update_submitted>
  <last_update_submitted_qc>June 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Yundai Chen</name_title>
    <organization>Chinese PLA general hospital</organization>
  </responsible_party>
  <keyword>Contrast Induced Nephropathy</keyword>
  <keyword>CIN</keyword>
  <keyword>Cardiac Catheterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

